Company: MYGN
Filing Date: 2025-02-28
Form Type: 10-K
Source: 0000899923-25-000019
Chunk: 215

Company: MYRIAD GENETICS INC
Filing Date: 2025-02-28
Form: 10-K
Item: Item 8
Chunk 215
---
 $21.3 million was probable and estimable. In the year ended December 31, 2024, based on updated information, the Company determined that the payment is no longer probable and reversed the accrual on the Consolidated Statements of Operations. 

9.    PREFERRED AND COMMON STOCKHOLDERS' EQUITY

The Company is authorized to issue up to 5.0 million shares of preferred stock, par value $0.01 per share. There were no shares of preferred stock outstanding at December 31, 2024 and December 31, 2023. The Company is authorized to issue up to 150.0 million shares of common stock, par value $0.01 per share. In November 2023, the Company completed an underwritten public offering in which it sold 7.4 million shares of its common stock at a price of $17.00 per share, for gross proceeds of $126.5 million and net proceeds of $117.6 million. There were 91.3 million and 89.9 million shares of common stock issued and outstanding at December 31, 2024 and 2023, respectively.Shares of common stock issued and outstandingYears Ended December 31,(in millions)202420232022Beginning common stock issued and outstanding89.9 81.2 80.0 Common stock issued upon exercise of options, vesting of restricted stock units, and purchases under employee stock purchase plans1.4 1.3 1.2 Common stock issued for public offering— 7.4 — Common stock issued and outstanding at end of period91.3 89.9 81.2 

95

Table of Contents

10.    STOCK-BASED COMPENSATION

On November 30, 2017, the Company’s stockholders approved the adoption of the 2017 Employee, Director and Consultant Equity Incentive Plan (as amended, the “2017 Plan”). The 2017 Plan allows the Company, under the direction of the Compensation and Human Capital Committee (the "CHCC") of the Board of Directors, to make grants of restricted and unrestricted stock and stock unit awards to employees, consultants and directors. Stockholders have subsequently approved amendments to the 2017 Plan increasing the shares available to grant thereunder, including most recently at the Company's annual meeting of stockholders held on June 1, 2023, when stockholders